Menu Search
Equities

Xtant Medical Holdings Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
XMS:FRA

Xtant Medical Holdings Inc

Actions
  • Price (EUR)0.494
  • Today's Change-0.004 / -0.80%
  • Shares traded1.00k
  • 1 Year change-7.66%
  • Beta-0.3083
Data delayed at least 15 minutes, as of Feb 10 2026 07:04 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Xtant Medical Holdings, Inc. is a global medical technology company. The Company is focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. Its biomaterial products include OsteoSponge, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, OsteoVive, OsteoFactor, line of 3Demin products, as well as other allografts. It offers a comprehensive line of products that are used to treat a variety of spinal and sacroiliac conditions, including trauma, degeneration, deformity and tumor. Its key spinal implant product lines include Cervical products, Thoracolumbar products, Sacroiliac Joint products, and Interbody products.

  • Revenue in USD (TTM)133.08m
  • Net income in USD1.75m
  • Incorporated2006
  • Employees217.00
  • Location
    Xtant Medical Holdings Inc664 Cruiser LaneBELGRADE 59714United StatesUSA
  • Phone+1 (406) 388-0480
  • Fax+1 (302) 636-5454
  • Websitehttps://xtantmedical.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.